Company Filing History:
Years Active: 2006
Title: Graziella Mazza: Innovator in Tolerogenic Peptides
Introduction
Graziella Mazza is a prominent inventor based in Bristol, GB. She has made significant contributions to the field of immunology through her innovative research and development of tolerogenic peptides derived from myelin basic protein. Her work has the potential to impact therapeutic approaches for various diseases.
Latest Patents
Graziella Mazza holds 1 patent for her invention titled "Tolerogenic peptides from myelin basic protein." This patent describes a peptide capable of binding to an MHC class I or II molecule without further processing, known as an apitope. The patent specifically highlights peptides selected from the region 131-158 of myelin basic protein, including sequences such as 134-148, 135-149, and others. Additionally, the patent outlines the use of these peptides in pharmaceutical compositions and methods for treating or preventing diseases.
Career Highlights
Throughout her career, Graziella has worked with notable companies, including Apitope Technology (Bristol) Limited and Apitope Technology Limited. Her expertise in the field has allowed her to contribute to advancements in immunotherapy and peptide research.
Collaborations
Graziella has collaborated with esteemed colleagues, including David Wraith and Heather Streeter. These partnerships have further enriched her research and development efforts in the field of immunology.
Conclusion
Graziella Mazza's innovative work in the development of tolerogenic peptides showcases her commitment to advancing medical science. Her contributions have the potential to lead to significant breakthroughs in the treatment of autoimmune diseases.